PH12018501882A1 - Binding proteins and methods of use thereof - Google Patents

Binding proteins and methods of use thereof

Info

Publication number
PH12018501882A1
PH12018501882A1 PH12018501882A PH12018501882A PH12018501882A1 PH 12018501882 A1 PH12018501882 A1 PH 12018501882A1 PH 12018501882 A PH12018501882 A PH 12018501882A PH 12018501882 A PH12018501882 A PH 12018501882A PH 12018501882 A1 PH12018501882 A1 PH 12018501882A1
Authority
PH
Philippines
Prior art keywords
methods
binding proteins
protein
gfral
antibodies
Prior art date
Application number
PH12018501882A
Other languages
English (en)
Inventor
Wenyan Shen
Jie Tang
Yan Wang
Hugo Matern
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of PH12018501882A1 publication Critical patent/PH12018501882A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PH12018501882A 2016-03-31 2018-09-04 Binding proteins and methods of use thereof PH12018501882A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31
PCT/US2017/020654 WO2017172260A1 (en) 2016-03-31 2017-03-03 Binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12018501882A1 true PH12018501882A1 (en) 2019-01-28

Family

ID=59966343

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018501882A PH12018501882A1 (en) 2016-03-31 2018-09-04 Binding proteins and methods of use thereof

Country Status (19)

Country Link
US (4) US10174119B2 (enExample)
EP (1) EP3436068A4 (enExample)
JP (3) JP7021099B2 (enExample)
KR (2) KR102370762B1 (enExample)
CN (2) CN109715206B (enExample)
AU (3) AU2017241161B2 (enExample)
BR (1) BR112018068898A2 (enExample)
CA (1) CA3016035A1 (enExample)
CL (1) CL2018002687A1 (enExample)
CO (1) CO2018009995A2 (enExample)
IL (1) IL261666B2 (enExample)
MX (2) MX2018011503A (enExample)
MY (1) MY194669A (enExample)
NZ (1) NZ785098A (enExample)
PE (1) PE20190126A1 (enExample)
PH (1) PH12018501882A1 (enExample)
SG (1) SG11201807279QA (enExample)
TW (2) TWI815793B (enExample)
WO (1) WO2017172260A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US20190234935A1 (en) * 2016-10-12 2019-08-01 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
EP3833974A2 (en) * 2018-08-10 2021-06-16 Novartis AG Gfral extracellular domains and methods of use
CA3129059A1 (en) * 2019-02-05 2020-08-13 The Trustees Of The University Of Pennsylvania Peptide ligands of the gdnf family receptor a-like (gfral) receptor
WO2020227640A1 (en) * 2019-05-08 2020-11-12 Agilvax, Inc. Compositions and methods related to xct antibodies
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
WO2021050978A1 (en) * 2019-09-11 2021-03-18 University Of Cincinnati Treatment of skin blistering diseases using antibodies
AU2021284131B2 (en) * 2020-06-04 2025-05-29 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
KR102708796B1 (ko) 2020-06-04 2024-09-26 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
WO2022178416A1 (en) * 2021-02-22 2022-08-25 Northwestern University Anti-cd73 monoclonal antibodies
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) * 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
CN117693525A (zh) * 2021-06-30 2024-03-12 上海津曼特生物科技有限公司 抗gfral抗体及其应用
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
EP4406972A1 (en) * 2021-09-24 2024-07-31 Daegu Gyeongbuk Institute Of Science and Technology Gfral-antagonistic antibody having improved affinity, and use thereof
KR102864956B1 (ko) * 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
JP2025506341A (ja) * 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ３８結合分子及びその使用
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN119095876A (zh) * 2022-03-28 2024-12-06 科赫鲁斯生物科学有限公司 抗ilt4组合物和方法
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
WO2025029768A1 (en) 2023-07-31 2025-02-06 Ngm Biopharmaceuticals, Inc. Methods of treating nausea and vomiting disorders using anti-gfral antibodies
CN117209596B (zh) * 2023-09-01 2024-11-26 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools
WO2025244462A1 (ko) * 2024-05-24 2025-11-27 한국과학기술원 Gfral을 표적으로 하는 단일클론 항체 및 이의 용도

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
EP0879247A4 (en) 1995-11-13 2002-01-30 Carlos Ibanez RECEIVERS OF THE NEUROTROPHIC FACTOR DERIVED FROM GLIAL CELL LINES
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
EP0950105A1 (en) 1996-09-11 1999-10-20 Ortho-McNeil Pharmaceutical, Inc. Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
AU741208B2 (en) 1997-05-22 2001-11-22 Urmas Arumae Glial cell line-derived neurotrophic factor receptors
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
EP1100822A1 (en) 1998-07-23 2001-05-23 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
EP1119772A1 (en) 1998-10-01 2001-08-01 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
US6905817B1 (en) 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PT1179067E (pt) 1999-05-17 2007-01-31 Biopharm G Biotechnolo Entwi V Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
AU5018201A (en) 2000-04-20 2001-11-07 St Vincents Hospital Sydney Lt Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
EP1354042A2 (en) 2000-12-29 2003-10-22 Curagen Corporation Proteins and nucleic acids encoding same
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2002072608A2 (en) 2001-03-09 2002-09-19 University Of Chicago POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS
EP2845864A3 (en) 2001-05-11 2015-06-10 Amgen, Inc Peptides and related molecules that bind to TALL - 1
GB0115195D0 (en) 2001-06-21 2001-08-15 Bae Systems Plc Split-pin drill jig
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
US20100285016A1 (en) 2002-03-05 2010-11-11 Genentech, Inc. PRO34128 nucleic acids
US7247446B2 (en) 2002-03-05 2007-07-24 Genentech, Inc. PRO34128 nucleic acids
US7642242B2 (en) 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
AU2003295424A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
CN1241941C (zh) * 2003-11-21 2006-02-15 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
ES2555956T3 (es) 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
SI2004683T1 (sl) 2006-03-24 2016-09-30 Biogen Hemophilia Inc. Pc5 kot encim za obdelavo propeptida faktorja ix
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
NZ574423A (en) 2006-07-26 2012-04-27 Pepscan Systems Bv Immunogenic compounds and protein mimics
CN106018820B (zh) 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
JP5478254B2 (ja) * 2006-10-19 2014-04-23 ジェネンテック， インコーポレイテッド 抗ノッチ３アゴニスト抗体とノッチ３関連疾患の治療におけるその使用
EP2144639B1 (en) 2007-04-25 2012-08-22 Stem Cells Spin S.A. New stem cell line and its application
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
JP2010536717A (ja) 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
CN101896192A (zh) 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
JP5272011B2 (ja) 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
WO2009087190A1 (en) 2008-01-08 2009-07-16 Roche Diagnostics Gmbh Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
EP2318844A1 (en) 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
US20120107420A1 (en) 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
CN107435038B (zh) 2008-10-31 2021-07-09 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
SG173632A1 (en) 2009-02-12 2011-09-29 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
KR101558642B1 (ko) 2009-02-24 2015-10-12 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
WO2011005621A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
US20130323835A1 (en) 2009-07-15 2013-12-05 Zirus, Inc. Mammalian Genes Involved in Infection
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
MX2012005168A (es) 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2540827A4 (en) * 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd ANTI-ICAM3 ANTIBODIES AND USE THEREOF
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
EP3225994A1 (en) 2010-08-26 2017-10-04 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
SMT201700025T1 (it) 2011-04-13 2017-03-08 Bristol Myers Squibb Co Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
EP2863910B1 (en) 2012-06-20 2020-03-11 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
WO2014011955A2 (en) * 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
KR20150038012A (ko) 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
SI2900263T1 (sl) 2012-09-26 2019-09-30 Julius-Maximilians-Universitaet Wuerzburg Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (gdf-15)
CA2888345C (en) * 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
DE102013100322A1 (de) 2013-01-14 2014-07-17 Claas Selbstfahrende Erntemaschinen Gmbh Schneidwerk
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN105579469A (zh) * 2013-06-10 2016-05-11 默沙东公司 Cmv中和抗原结合蛋白
JP6509852B2 (ja) 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
US20190234935A1 (en) 2016-10-12 2019-08-01 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
PE20211412A1 (es) 2018-08-20 2021-08-02 Pfizer Anticuerpos anti-gdf15, composiciones y metodos de uso
AU2021284131B2 (en) 2020-06-04 2025-05-29 Daegu Gyeongbuk Institute Of Science And Technology GFRAL-antagonistic antibody and use thereof
US11845791B2 (en) 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia

Also Published As

Publication number Publication date
KR102630655B1 (ko) 2024-01-30
JP7021099B2 (ja) 2022-02-18
US20220073627A1 (en) 2022-03-10
KR102370762B1 (ko) 2022-03-04
CN117986363A (zh) 2024-05-07
JP2024156852A (ja) 2024-11-06
WO2017172260A1 (en) 2017-10-05
EP3436068A1 (en) 2019-02-06
JP7610541B2 (ja) 2025-01-08
US12180289B2 (en) 2024-12-31
KR20220032645A (ko) 2022-03-15
IL261666A (en) 2018-10-31
AU2025234197A1 (en) 2025-10-16
US20170306031A1 (en) 2017-10-26
AU2017241161A1 (en) 2018-09-20
US10975154B2 (en) 2021-04-13
RU2018132739A (ru) 2020-04-30
US20190092866A1 (en) 2019-03-28
IL261666B2 (en) 2024-09-01
US10174119B2 (en) 2019-01-08
CN109715206A (zh) 2019-05-03
AU2017241161B2 (en) 2022-05-26
BR112018068898A2 (pt) 2019-01-22
MX2024011328A (es) 2024-11-08
JP2019513018A (ja) 2019-05-23
NZ785098A (en) 2025-09-26
US20250188174A1 (en) 2025-06-12
KR20180130524A (ko) 2018-12-07
PE20190126A1 (es) 2019-01-17
NZ745635A (en) 2024-03-22
TW202423985A (zh) 2024-06-16
EP3436068A4 (en) 2020-01-15
CA3016035A1 (en) 2017-10-05
RU2018132739A3 (enExample) 2020-09-02
TWI815793B (zh) 2023-09-21
AU2022224794B2 (en) 2025-07-03
AU2022224794A1 (en) 2022-09-22
SG11201807279QA (en) 2018-09-27
CN109715206B (zh) 2023-11-07
CO2018009995A2 (es) 2018-12-14
TWI897070B (zh) 2025-09-11
IL261666B1 (en) 2024-05-01
MX2018011503A (es) 2018-11-09
TW201809011A (zh) 2018-03-16
JP2022088355A (ja) 2022-06-14
CL2018002687A1 (es) 2019-05-10
WO2017172260A8 (en) 2017-12-28
MY194669A (en) 2022-12-12

Similar Documents

Publication Publication Date Title
PH12018501882A1 (en) Binding proteins and methods of use thereof
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
ZA201708265B (en) Tigit-binding agents and uses thereof
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
WO2017019957A3 (en) Binding proteins and methods of use thereof
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения